29.23
-0.54%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Pfizer
From its filings with the US Securities and Exchange Commission
Pfizer is based in New York, New York and is incorporated in Delaware. Its shares trade on NYSE under the ticker PFE. It is a member of the S&P 500. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $62.58bn and net income of $7.77bn. At that date it held total assets of $208.16bn and shareholders' equity of $86.48bn.
Most of our revenues come from the manufacture and sale of biopharmaceutical products. We believe that our medicines and vaccines provide significant value for healthcare providers and patients through improved treatment of diseases and improvements in health, wellness and productivity as well as by reducing other healthcare costs, such as emergency room visits or hospitalizations. We seek to enhance the value of our medicines and vaccines and actively engage in dialogues about how we can best work with patients, physicians and payors to prevent and treat disease and improve outcomes. We seek to maximize patient access and evaluate our pricing arrangements and contracting methods with payors to minimize adverse impact on our revenues within the current legal and pricing structures.
We are committed to fulfilling our purpose: Breakthroughs that change patients’ lives. Our purpose fuels everything we do and reflects both our passion for science and our commitment to patients. As a science-driven global biopharmaceutical company, we remain focused on advancing our product pipeline, supporting our marketed brands and deploying capital responsibly, with a focus on initiatives that can help contribute to our long-term revenue and future growth.
Quoted from its 10-K, filed 26 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 17 Jan 1944
- Employees
- 75,000
- Website
- pfizer.com ↗
- Head office
- 66 HUDSON BOULEVARD EAST, NEW YORK, NY, 10001-2192
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Dr. Albert BourlaChairman of the Board, Chief Executive Officer, since 2014$24.6m
- Mr. David DentonExecutive Vice President, Chief Financial Officer$8.1m
- Ms. Payal SahniExecutive Vice President, Chief People Experience Officer
- Ms. Lidia FonsecaExecutive Vice President, Chief Digital and Technology Officer
- Mr. Alexandre De GermayExecutive Vice President, Chief International Commercial Officer
- Mr. Douglas LanklerExecutive Vice President, Chief Legal Officer$5.5m
- Mr. Aamir MalikExecutive Vice President, Chief US Commercial Officer$8.3m
- Mr. Michael McdermottExecutive Vice President, Chief Global Supply Officer
- Ms. Sally SusmanExecutive Vice President, Chief Corporate Affairs Officer
- Dr. Chris BoshoffChief Scientific Officer, President - Research & Development$7.9m
- Mr. Shantanu NarayenLead Independent Director$445,000
- Mr. Ronald BlaylockIndependent Director$360,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 73
- Environment
- 81
- Social
- 87
- Governance
- 50
- Direct emissions (scope 1)
- 620,124 t
- Energy emissions (scope 2)
- 500,077 t
- Value chain emissions (scope 3)
- 4,338,487 t
- Women in the workforce
- 50.2%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Pfizer Inc. possesses several strengths that contribute to its success in the pharmaceutical industry. One of its key strengths is its extensive portfolio of innovative drugs and treatments. The company invests heavily in research and development, allowing it to continuously develop and introduce new products to the market. Pfizer's strong brand reputation and global presence also contribute to its competitive advantage.
- Another major strength is Pfizer's robust financial position. The company has a solid revenue stream, driven by the high demand for its products, and maintains a strong profitability margin. This financial stability enables Pfizer to invest in strategic acquisitions and partnerships, further strengthening its position in the industry.
Weaknesses
- Despite its strengths, Pfizer Inc. also faces certain weaknesses that need to be addressed. One weakness is its heavy reliance on a few key products for a significant portion of its revenue. This exposes the company to risks associated with patent expirations and competition from generic drug manufacturers. Pfizer needs to focus on diversifying its product portfolio to reduce this dependency.
- Another weakness is the potential negative impact of regulatory changes and legal issues on Pfizer's operations. The pharmaceutical industry is subject to strict regulations, and any change or legal challenge can disrupt Pfizer's business activities and profitability. Close monitoring of regulatory developments and proactive compliance strategies are essential to mitigate these risks.
Opportunities
- Pfizer Inc. has several opportunities to capitalize on in the constantly evolving pharmaceutical market. One significant opportunity lies in the growing demand for personalized medicine and targeted therapies. Pfizer can leverage its expertise and research capabilities to develop innovative treatments that cater to specific patient populations, creating a competitive edge in the market.
- Furthermore, the increasing focus on healthcare and medical advancements presents an opportunity for Pfizer to expand into emerging markets with high growth potential. By targeting underserved regions, the company can tap into new customer segments and drive revenue growth. Strategic collaborations with local healthcare providers and governments can further enhance Pfizer's market penetration in these regions.
Threats
- Like any other company in the pharmaceutical industry, Pfizer Inc. faces several threats that could impact its business. One major threat is the intense competition within the market. The industry is highly competitive, with numerous pharmaceutical companies striving to develop breakthrough drugs and gain market share. Pfizer needs to continuously innovate and stay ahead to maintain its competitive position.
- Additionally, the potential risk of counterfeit drugs poses a threat to Pfizer's reputation and revenue. Counterfeit drugs can harm patients and erode trust in the company's products. Pfizer should strengthen its supply chain security and invest in advanced technologies to detect and combat counterfeit drugs effectively.
- Moreover, changes in healthcare policies and pricing regulations can significantly impact Pfizer's profitability. Government policies aimed at cost containment or price controls can restrict the company's ability to set prices for its products, thereby affecting its financial performance. Continuous monitoring of these policies and proactive engagement with policymakers is crucial to minimize potential risks.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.